e2vc’s Post

🚨 LATEST BIOTECH NEWS 🚨 Mirador Therapeutics has raised over $400 million across its seed and Series A rounds, one of the largest early-stage financings in biotech history. The funds will advance a pipeline of precision medicines for immune-related diseases and support Mirador’s proprietary Mirador360 discovery platform. The rounds were led by ARCH Venture Partners, with participation from OrbiMed and Sanofi Ventures. CEO Mark McKenna, formerly head of Prometheus Biosciences (acquired by Merck for $10.8B in 2023), said the financing provides “cash runway for many years” and will allow the company to move multiple programs into the clinic. Mirador’s focus spans skin, lung, and gastrointestinal diseases, each linked to genetic and molecular markers identified through its platform. Mirador360 integrates genomic data, molecular profiling, and machine learning to design therapies tailored to individual patient subtypes, anchored in the principle that every program must have a clear genetic association to disease. The raise comes as biotech funding shows early signs of recovery after a sharp downturn in 2023, when U.S. biopharma venture activity fell 25% year over year. Investors are increasingly backing data-driven, precision medicine models that combine AI and human biology, a trend exemplified by Mirador’s approach. For context, this is one of the few early-stage rounds exceeding $400M, signaling renewed confidence in the next generation of precision immunology companies emerging from major academic and industry ecosystems. 👉 Follow Sadhna Bokhiria & KIRIA Research for data-driven insights on biotech, pharma, and the companies shaping the future of precision medicine. #Biotech #Pharma #MiradorTherapeutics #ARCHVenturePartners #KIRIAResearch #KIRIA

Ropes & Gray was proud to sponsor the Align Summit, MassBio’s annual early-stage and funder partnering conference, which took place yesterday in Boston. The event brought together investors and biotech startups to advance next-generation therapies. This year’s program featured 56 emerging life sciences companies presenting across tracks focused on AI and machine learning in drug discovery, multi-specific therapeutics, precision therapies, and early-stage biotech, alongside thought leadership sessions and partnering meetings. Learn more here: https://lnkd.in/gfUN3pvH

At #FierceBiotechWeek 2025, Christelle Huguet, #Ipsen, Head of R&D, joined industry leaders to explore the future of biotech innovation, from capital efficiency to partnerships and patient-driven science. Our focus is clear: deliver transformative medicines faster to patients by combining our scientific expertise, agile size, and a partner-led discovery model. At Ipsen, we’re: ·      Advancing strategic R&D fuelled by focus, partnerships, and purpose. ·      Investing smartly to maximise patient impact. ·      Partnering for progress through science with purpose.   From rare disease and neuroscience to oncology, and from data science to discovery, Ipsen’s R&D is focused on one goal: bringing transformative medicines to patients faster. We seek partners who share our vision of co-creating pioneering science. Learn more about Ipsen’s R&D: https://lnkd.in/dvuwH8Cn

The Future of Healthcare Is Being Built Through M&A In today’s healthcare and biotechnology landscape, mergers and acquisitions are no longer just financial moves; they’re innovation catalysts. From biotech startups pioneering cell and gene therapies to global healthcare giants expanding R&D pipelines, strategic collaborations are reshaping how breakthroughs reach patients. These deals are helping companies: ✅ Accelerate drug discovery and approvals ✅ Expand biomanufacturing and digital capabilities ✅ Unlock data-driven insights for personalized medicine As organizations unite science, technology, and scale, the line between research and real-world application continues to blur, creating a more connected, efficient, and patient-centric healthcare ecosystem. The next decade won’t be defined by who competes best, but by who collaborates smartest. Read the full outlook: https://lnkd.in/gGC9z_mW #HealthcareInnovation #Biotechnology #MergersAndAcquisitions #HealthcareTransformation #DigitalHealth #LifeSciences #BiotechGrowth

Partnerships accelerate progress. Orphan Therapeutics Accelerator is pioneering a faster, more systematic way to identify promising rare disease programs — and we’re proud that Vibe Bio’s AI-powered analysis played a role. Using our platform, the OTxL team rapidly assessed scientific rationale, IP strength, clinical data, and development feasibility across a broad landscape of potential assets — helping them focus resources where they’ll have the greatest impact. This case study shows how technology and collaboration can shorten the path from possibility to progress. 🔗 in first comment #RareDisease #Biotech #AI #casestudy

This sounds exciting! “🤖 𝗘𝗩𝗢𝗧𝗘𝗖 + 𝗕𝗜𝗢𝗡𝗧𝗘𝗖𝗛:  AI alliance for next-gen oncology targets - The two German heavyweights announced a strategic partnership to integrate Evotec’s AI-driven discovery platform with BioNTech’s development engine. Their goal: accelerate target identification and validation in precision oncology.”

Helex Raises $3.5M to Advance Kidney Research 🧬 A major step forward for biotech innovation! 🧪 US-based Helex has raised $3.5 million to accelerate its preclinical kidney program, aiming to advance early-stage treatments for kidney disorders. 👏 Congratulations to the Helex team from Jobs Territory for driving medical progress and pushing the frontiers of healthcare research. #Biotech #HealthcareInnovation #FundingNews #MedicalResearch #JobsTerritory

This year’s Fierce Biotech "Biotech Graveyard" article is a sobering snapshot of the sector’s volatility. ~16 companies shuttered completely, and 3 more are listed as "living dead", caught in survival mode with no clear path forward. It’s not just a funding winter anymore. It’s a strategic reckoning. Some common themes: Modality fatigue: cell therapy, micro-proteins, and tRNA startups struggled despite scientific promise. Lack of translational velocity: great biology without clinical traction or clear commercial strategy didn’t survive. Macro pressure: funding pullback, regulatory uncertainty, and high burn rates created a perfect storm. As Fierce Biotech puts it, even companies with “star-studded boards and top science” weren’t spared. For those of us working in translational science, drug discovery, and early development this is a call to sharpen our impact. Science alone isn’t enough. We need to build bridges between mechanism and medicine, fast.

𝗕𝗜𝗢𝗧𝗘𝗖𝗛 𝗜𝗡 𝗚𝗘𝗥𝗠𝗔𝗡𝗬 - 𝗛𝗘𝗔𝗗𝗟𝗜𝗡𝗘𝗦 𝗧𝗛𝗜𝗦 𝗪𝗘𝗘𝗞 (CW41) 🤖 𝗘𝗩𝗢𝗧𝗘𝗖 + 𝗕𝗜𝗢𝗡𝗧𝗘𝗖𝗛:  AI alliance for next-gen oncology targets - The two German heavyweights announced a strategic partnership to integrate Evotec’s AI-driven discovery platform with BioNTech’s development engine. Their goal: accelerate target identification and validation in precision oncology. 🖲️ 𝙁𝙤𝙧 𝘾𝙤𝙣𝙩𝙚𝙭𝙩: Germany’s biotech ecosystem is quietly becoming an AI hotspot — less noise than in the U.S., but with deep translational capabilities and data integrity standards that make this model highly scalable. 🧪 𝗕𝗔𝗬𝗘𝗥 𝗥𝗘𝗦𝗧𝗥𝗨𝗖𝗧𝗨𝗥𝗘𝗦 𝗜𝗦𝗧 𝗣𝗛𝗔𝗥𝗠𝗔 𝗥&𝗗 𝗙𝗢𝗢𝗧𝗣𝗥𝗜𝗡𝗧: cell & gene therapy hubs in Berlin and Wuppertal - Bayer is consolidating discovery programs and focusing R&D investment into two German innovation clusters dedicated to advanced therapies. 🔎 𝙁𝙤𝙧 𝘾𝙤𝙣𝙩𝙚𝙭𝙩: This is a signal move from “diversification” toward “focus.” Big Pharma in Europe is streamlining research around modular platforms rather than broad portfolios — expect more partnerships with start-ups and CDMOs in the ATMP space! 🏦 𝗣𝗘𝗜 𝗗𝗥𝗔𝗙𝗧𝗦 𝗡𝗔𝗧𝗜𝗢𝗡𝗔𝗟 𝗚𝗨𝗜𝗗𝗘𝗟𝗜𝗡𝗘 𝗙𝗢𝗥 𝗖𝗢𝗠𝗣𝗔𝗥𝗔𝗕𝗜𝗟𝗜𝗧𝗬 𝗢𝗙 𝗔𝗧𝗠𝗣𝘀 𝗔𝗙𝗧𝗘𝗥 𝗠𝗔𝗡𝗨𝗙𝗔𝗖𝗧𝗨𝗥𝗜𝗡𝗚 𝗖𝗛𝗔𝗡𝗚𝗘𝗦 - The Paul-Ehrlich-Institut has released a draft guidance clarifying quality and analytical expectations when process modifications occur during ATMP development. 📓 𝙁𝙤𝙧 𝘾𝙤𝙣𝙩𝙚𝙭𝙩: This is a pragmatic step that closes a long-standing gap between GMP reality and regulatory interpretation. For developers, it means earlier comparability planning and tighter integration between process engineering and clinical strategy — precisely where many programs stumble. #biotech #atmps #innovation #weekly #germany

𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝗶𝘀 𝗳𝗶𝗻𝗮𝗹𝗹𝘆 𝘄𝗮𝗸𝗶𝗻𝗴 𝘂𝗽. After two brutal years of downturn, venture investment in biotech jumped 71% in Q3 - from $1.8B to $3.1B - signaling real signs of life again. Biggest driver: Later-stage rounds. Series D deals exploded 60x quarter-over-quarter to $832M. Kriya Therapeutics, Inc. led the pack with $320M for its gene therapy platform. Odyssey Therapeutics followed with $213M for autoimmune drugs. Interest rate cuts are helping too - making capital cheaper and risk appetites stronger. Still, Trump’s tariffs and NIH/FDA cuts are clouding the outlook. But the rebound in M&A - up 36% to $43.2B - says investors are betting on a comeback. Feels like biotech winter might finally be thawing.